Eli Lilly’s stock surges toward a 5th straight record after an earnings beat and upbeat outlook

  • 📰 MarketWatch
  • ⏱ Reading Time:
  • 24 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 13%
  • Publisher: 97%

United States News News

United States United States Latest News,United States United States Headlines

Tomi Kilgore is MarketWatch's deputy investing and corporate news editor and is based in New York. You can follow him on Twitter @TomiKilgore.

Shares of Eli Lilly and Co. LLY, +5.77% rallied toward a fifth-straight record close in premarket trading Tuesday, after the drug maker’s fourth-quarter earnings beat expectations, helped by a 16% jump in prices, and provided an upbeat 2024 revenue outlook. Net income rose to $2.19 billion, or $2.42 a share, from $1.94 billion, or $2.14 a share, in the year-ago period. Excluding nonrecurring items, adjusted earnings per share of $2.49 beat the FactSet consensus of $2.30. Revenue jumped 28.

95 billion, as prices increased 16%, volume rose 11% and currency translation added 1% growth. Sales of the company’s obesity drug Zepbound total $175.8 million, while there were no recorded sales of Covid-19 antibodies. For 2024, the company expects adjusted EPS of $12.20 to $12.70, which surrounds the current FactSet consensus of $12.39, and expects revenue of $40.4 billion to $41.6 billion, which is above expectations of $39.3 billion. The stock has run up 18.

 

Thank you for your comment. Your comment will be published after being reviewed.
Please try again later.
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:

 /  🏆 3. in US

United States United States Latest News, United States United States Headlines